Neratinib as a Potential Therapeutic for Mutant RAS and Osimertinib-Resistant Tumours
Neratinib was developed as an irreversible catalytic inhibitor of ERBB2, which also acts to inhibit ERBB1 and ERBB4. Neratinib is U.S. Food and Drug Administration (FDA)-approved as a neo-adjuvant therapy for use in HER2+ breast cancer. More recently, chemical biology analyses and the authors’ own...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
European Medical Journal
2022-09-01
|
| Series: | European Medical Journal |
| Online Access: | https://www.emjreviews.com/flagship-journal/article/neratinib-as-a-potential-therapeutic-for-mutant-ras-and-osimertinib-resistant-tumours-j190322/ |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|